ArticleNeurology(R) neuroimmunology & neuroinflammation2021
Fatigue in Survivors of Autoimmune Encephalitis.
Article in Neurology(R) neuroimmunology & neuroinflammation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Investigating health related quality of life and clinical measures in autoimmune encephalitis: a systematic review.Orphanet journal of rare diseases · 2025Pooled it
- Clinical Outcome Assessments in Encephalitis: A Systematic ReviewNeurology(R) neuroimmunology & neuroinflammation · 2024Pooled it
- Long-term maintenance of mycophenolate mofetil in anti-NMDA receptor encephalitis (LEARN): a multicentre, open-label, blinded-endpoint, randomised controlled trial.Journal of neurology, neurosurgery, and psychiatry · 2025Trial
- A new Patient-Reported Outcome Scale to assess autoimmune Encephalitis: PROSE.Annals of neurology · 2026Article
- Long-Term Outcomes in Autoimmune Encephalitis: A Nationwide, Clinical Study in Denmark.Neurology(R) neuroimmunology & neuroinflammation · 2026Article
- The Treatment of Antibody-Mediated Encephalitis: Current, Future Therapies, Unmet Need and Patient Management.Advances in therapy · 2026Review
- A qualitative exploration of patient experiences living with autoimmune encephalitis.Scientific reports · 2026Article
- Uncertainty as an operative construct and treatment target in functional neurological disorder.Frontiers in psychiatry · 2026Article
- The relationship between patient-reported quality of life and clinician-rated outcome scores in patients with autoimmune encephalitis: a study of the Australian Autoimmune Encephalitis Consortium.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025Article
- Autoimmune encephalitis.Nature reviews. Disease primers · 2025Review
- Hypersomnolence in focus: a white paper of the 6th Think Tank World Sleep Forum.Sleep medicine · 2025Review
- Adaptogens in Long-Lasting Brain Fatigue: An Insight from Systems Biology and Network Pharmacology.Pharmaceuticals (Basel, Switzerland) · 2025Review
- A new mindfulness and psycho-educative program for treatment of brain fatigue, evaluated after an acquired brain injury and multiple sclerosis.Health psychology and behavioral medicine · 2025Article
- Patient-Reported Outcome Measures in NMDA Receptor Encephalitis.Neurology(R) neuroimmunology & neuroinflammation · 2025Observational
- Long-Term Cognitive, Functional, and Patient-Reported Outcomes in Patients With Anti-NMDAR Encephalitis.Neurology · 2024Article
- Assessment of long-term psychosocial outcomes in N-methyl-D-aspartate receptor encephalitis - the SAPIENCE study protocol.BMC neurology · 2024Observational
- Fatigue predicts quality of life after leucine-rich glioma-inactivated 1-antibody encephalitis.Annals of clinical and translational neurology · 2024Article
- Outcome and Sequelae of Autoimmune Encephalitis.Journal of clinical neurology (Seoul, Korea) · 2024Review
- The Patient Perspective in Encephalitis Research.Neurology(R) neuroimmunology & neuroinflammation · 2024Article
- Innovation and optimization in autoimmune encephalitis trials: the design and rationale for the Phase 3, randomized study of satralizumab in patients with NMDAR-IgG-antibody-positive or LGI1-IgG-antibody-positive autoimmune encephalitis (CIELO).Frontiers in neurology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesTo evaluate the impact of fatigue after autoimmune encephalitis, determine associations with patients' characteristics, and identify factors that contribute to its development.
methodsIn a first cohort recruited via several encephalitis support organizations, self-reported questionnaires were used to evaluate fatigue, depression, and sleep quality in adults after autoimmune encephalitis. In a second cohort where more in-depth clinical characterization could be performed, adults with encephalitis from 2 tertiary hospitals were evaluated using the same questionnaires. Patients' characteristics were retrospectively captured.
resultsIn the first cohort (mean [SD] age; 43 [16] years, 220 [65%] female), 220 of 338 participants (65%) reported fatigue, 175 of 307 (57%) depression, and 211 of 285 (74%) poor sleep quality. In the second cohort (48 [19] years; 43 [50%] women), 42 of 69 participants (61%) reported fatigue, whereas 23 of 68 (34%) reported depression and 44 of 66 (67%) poor sleep quality, despite more than 80% having "good" modified Rankin scale (mRS) scores (0-2). Individuals with anti-NMDA receptor encephalitis reported lower fatigue scores than those with other autoimmune encephalitis types. In a multivariate analysis examining factors at discharge that might predict fatigue scores, only anti-NMDA receptor encephalitis was a (negative) predictor of fatigue and remained so when potential confounders were included. DISCUSSION: The impact of fatigue after autoimmune encephalitis is prominent and not fully accounted for by depression or sleep quality, nor adequately captured by mRS scores for disability. Fatigue is pervasive across autoimmune encephalitis, although lower scores are reported in anti-NMDA receptor encephalitis. Fatigue should be screened routinely, considered as an outcome measure in clinical trials, and further studied from a mechanistic standpoint.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.